The Parkinsonian Neurotoxin 1-Methyl-4-Phenylpyridinium (MPP+) Mediates Release of L-3,4-Dihydroxyphenylalanine (L-DOPA) and Inhibition of L-DOPA Decarboxylase in the Rat Striatum: A Microdialysis Study

Chemical Research in Toxicology

Volumn 16, Issue 10, 2003, Pages 1372-1384

  Foster, Steven B ^a   Wrona, Monika Z ^a   Han, Jilin ^a   Dryhurst, Glenn ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CYSTEINE; DISULFIDE; DOPAMINE; EXCITOTOXIN; GLUTAMIC ACID; GLUTATHIONE; HYDROXYL RADICAL; LEVODOPA; METHAMPHETAMINE; NEUROTOXIN; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; SULFIDE; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; EXTRACELLULAR SPACE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; IN VITRO STUDY; MALE; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; OXIDATION; PARKINSONISM; PERFUSION; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIOXIDANTS; BODY TEMPERATURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPA DECARBOXYLASE; HYDROXYINDOLEACETIC ACID; LEVODOPA; MALE; MANNITOL; MICRODIALYSIS; NEOSTRIATUM; PARKINSONIAN DISORDERS; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; SALICYLATES; SEROTONIN; TIME FACTORS;

ANIMALIA; PARKINSONIA;

EID: 0142139278     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx030015l     Document Type: Article

References (76)

1. Gerlach, M., and Riederer, P. (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103, 987-1041.
2. Gerlach, M., Riederer, P., Przuntek, H., and Youdim, M. B. H. (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208, 278-286.
3. Langston, J. W., and Irwin, I. (1986) MPTP: current concepts and controversies. Clin. Neuropharmacol. 9, 485-507.
4. +. Neurosci. Lett. 75, 323-328.
5. Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., and Snyder, S. H. (1985) Parkinsonian-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 82, 2173-2177.
6. Ramsay, R. R., Dadgar, J., Trevor, A., and Singer, T. P. (1986) Energy driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci. 39, 581-588.
7. +) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J. Neurochem. 56, 1184-1190.
8. Chan, P., Delanney, L. E., Irwin, I., Langston, J. W., and Di Monte, D. (1991) Rapid ATP loss caused by MPTP in mouse brain. J. Neurochem. 57, 348-351.
9. +) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170, 1049-1055.
10. Mytilineou, C., Leonardi, E. T. K., Kramer, B. C., Jamindar, T., and Olanow, C. W. (1999) Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures. J. Neurochem. 73, 112-119.
11. Przedborski, S., Kostic, V., Jackson-Lewis, V., Naini, A. B., Simoneltá, S., Fah, S., Carlson, E., Epstein, C. J., and Cadet, J. L. (1992) Transgenic mice with increased Cu/Zn superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12, 1658-1667.
12. Ara, J., Przedborski, S., Naini, A. B., Jackson-Lewis, V., Trifiletti, R. R., Horwitz, J., and Ischiropoulos, H. (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc. Natl. Acad. Sci. U.S.A. 95, 7659-7663.
13. Pennathur, S., Jackson-Lewis, V., Przedborski, S., and Heinecke, J. W. (1999) Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem. 274, 34621-34628.
14. Blanchard-Fillion, B., Souza, J. M., Friel, T., Jiang, G. C. T., Vrana, K., Sharov, V., Barrón, L., Schöneich, C., Quijano, C., Alvarez, B., Radi, R., Przedborski, S., Fernando, G. S., Horwitz, J., and Ischiropoulos, H. (2001) Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J. Biol. Chem. 276, 46017-46023.
15. Mandir, A. S., Przedborski, S., Jackson-Lewis, V., Wang, Z.-Q., Simbulan-Rosenthal, C. M., Smulson, M. E., Hoffman, B. E., Guestella, D. B., Dawson, V. L., and Dawson, T. M. (1999) Poly(ADP-ribose)polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 96, 5774-5779.
16. Bredt, D. S., Glatt, C. E., Hwang, P. M., Fotuhi, M., Dawson, T. M., and Snyder, S. H. (1991) Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 7, 615-624.
17. Przedborski, S., Jackson-Lewis, V., Yokohama, R., Shibata, T., Dawson, V. L., and Dawson, T. M. (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 93, 4565-4571.
18. Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., and Przedborski, S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat. Med. 5, 1403-1409.
19. Xia, Y., and Zweier, J. L. (1997) Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci. U.S.A. 94, 6954-6958.
20. +. J. Neural Transm. 89, 139-145.
21. +-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by nitric oxide synthase. NeuroReport 5, 2598-2600.
22. +-evoked hydroxyl radical formation but not dopamine efflux in rat striatum. J. Neural Transm. 106, 477-486.
23. Beckman J. S. (1996) Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 9, 836-844.
24. Lada, M. W., and Kennedy, R. T. (1996) Quantitative in vivo monitoring of primary amines in rat caudate nucleus using microdialysis coupled by a flow-gated interface to capillary electrophoresis with laser-induced fluorescence detection. Anal. Chem. 68, 2790-2797.
25. van der Vliet, A., O'Neill, C. A., Halliwel, B., Cross, C. E., and Kaur, H. (1994) Aromatic hydroxylation and nitration of phenylalanine and tyrosine by peroxynitrite. FEBS Lett. 339, 89-92.
26. Kaur, H., Whiteman, M., and Halliwell, B. (1997) Peroxynitrite-dependent aromatic hydroxylation and nitration of salicylate and phenylalanine. Is hydroxyl radical involved? Free Radical Res. 26, 71-82.
27. Themann, C., Teismann, P., Kuschinsky, K., and Ferger, B. (2001) Comparison of two independent aromatic hydroxylation assays in combination with intracerebral microdialysis to determine hydroxyl free radicals. J. Neurosci. Methods 108, 57-64.
28. Kerry, N., and Rice-Evans, C. (1999) Inhibition of peroxynitrite-mediated oxidation of dopamine by flavonoid and phenolic antioxidants and their structural relationships. J. Neurochem. 73, 247-253.
29. +. Eur. J. Pharmacol. 126, 345-346.
30. Han, J., Cheng, F.-C., Yang, Z., and Dryhurst, G. (1999) Inhibitors of mitochondrial respiration, iron (II) and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in the rat striatum and substantia nigra: potential implications to Parkinson's disease. J. Neurochem. 73, 1683-1695.
31. LaVoie, M. J., and Hastings, T. G. (1999) Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide and dopaminergic cell loss. J. Neurochem. 73, 2546-2554.
32. Zhang, F., and Dryhurst, G. (1995) Influence of glutathione on the oxidation chemistry of the catecholaminergic neurotransmitter dopamine. J. Electroanal. Chem. 398, 117-128.
33. Shen, X.-M., and Dryhurst, G. (1996) Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chem. Res. Toxicol. 9, 751-763.
34. Spencer, J. P. E., Whiteman, M., Jenner, P., and Halliwell, B. (2002) 5-S-Cysteinyl conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J. Neurochem. 81, 122-129.
35. Shen, X.-M., and Dryhurst, G. (1998) Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron and manganese dopaminergic neurotoxicity. Chem. Res. Toxicol. 11, 824-837.
36. Michel, P. P., Dandapani, B. K., Knusel, B., Sanchez-Ramos, J., and Hefti, F. (1990) Toxicity of 1-methyl-4-phenylpyridinium for rat dopaminergic neurons in culture: selectivity and irreversibility. J. Neurochem. 54, 1102-1109.
37. Sanchez-Ramos, J. R., Michel, P., Weiner, W. J., and Hefti, F. (1988) Selective destruction of cultured dopaminergic neurons from fetal rat mesencephalon by 1-methyl-4-phenylpyridinium: cytochemical and morphological evidence. J. Neurochem. 50, 1934-1944.
38. Giovanni, A., Sonsalla, P. K., and Heikkila, R. E. (1994) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 270, 1008-1014.
39. Santiago, M., Machado, A., and Cano, J. (2001) Validity of a quantitative technique to study striatal dopaminergic neurodegeneration by in vivo microdialysis. J. Neurosci. Methods 108, 181-187.
40. Santiago, M., Granero, L., Machado, A., and Cano, J. (1995) Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine. Eur. J. Pharmacol. 280, 251-256.
41. Reed, D. J., Babson, J. R., Beatty, P. W., Brodie, A. E., Ellis, W. W., and Potter, D. W. (1980) High-performance liquid chromatography analysis of nanomole levels of glutathione, glutathione disulfide and related thiols and disulfides. Anal. Biochem. 106, 55-62.
42. Wang, X. F., and Cynader, M. S. (2000) Astrocytes provide cysteine to neurons by releasing glutathione. J. Neurochem. 74, 1434-1442.
43. Hadjiconstantinou, M., Wemlinger, T. A., Sylvia, C. P., Hubble, J. P., and Neff, N. H. (1993) Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J. Neurochem. 60, 2175-2180.
44. Shen, X.-M., Xia, B., Wrona, M. Z., and Dryhurst, G. (1996) Synthesis, redox properties, in vivo formation and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Chem. Res. Toxicol. 9, 1117-1126.
45. Youngster, S. K., McKeown, K. A., Jin, Y. Z., Ramsay, R. R., Heikkila, R. E., and Singer, T. P. (1989) Oxidation of analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidases A and B and the inhibition of monoamine oxidases by the oxidation products. J. Neurochem. 53, 1837-1842.
46. Zimmer, L., Kodas, E., Guilloteau, D., Garreau, L., Besnard, J.-C., and Chalon, S. (2000) Microdialysis as a tool for in vivo study of dopamine transporter function in rat brains. J. Neurosci. Methods 103, 137-144.
47. Lada, M. W., and Kennedy, R. T. (1997) In vivo monitoring of glutathione and cysteine in rat caudate nucleus using microdialysis with capillary zone electrophoresis-laser induced fluorescence detection. J. Neurosci. Methods 72, 153-159.
48. +). Neurosci. Lett. 117, 129-133.
49. Lew, R., Malberg, J. E., Ricaurte, G. A., and Seiden, L. S. (1998) Evidence for and mechanism of action of neurotoxicity of amphetamine related compounds. In Highly Selective Neurotoxins: Basic and Clinical Applications (Kostrzewa, R. M., Ed.) pp 235-268, Humana Press, Totowa, N. J.
50. Chan, P., Di Monte, D. A., Luo, J.-J., Delanney, L. E., Irwin, I., and Langston, J. W. (1994) Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem. 62, 2484-2487.
51. O'Dell, S. J., Weihmuller, F. B., and Marshall, J. F. (1991) Multiple methamphetamine injections induce marked increases in extracellular dopamine which correlate with subsequent neurotoxicity. Brain Res. 564, 256-260.
52. Cadet, J. L., Sheng, P., Ali, S., Rothman, R., Carlson, E., and Epstein, C. (1994) Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 62, 380-383.
53. Imman, S. Z., Crow, J. P., Newport, G. D., Islam, F., Slikker, W., and Ali, S. F. (1999) Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: protective effects of peroxynitrite decomposition catalyst. Brain Res. 837, 15-21.
54. Giovanni, A., Liang, L. P., Hastings, T. G., and Zigmond, M. J. (1995) Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 64, 1819-1825.
55. Bowyer, J. F., Davies, D. L., Schmued, L., Broening, H. W., Newport, G. D., Slikker, W., and Holson, R. R. (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 268, 1571-1580.
56. Fukumura, M., Cappon, G. D., Pu, C., Broening, H. W., and Vorhees, C. V. (1998) A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 806, 1-7.
57. Cappon, G. D., Pu, C., and Vorhees, C. V. (2000) Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment. Brain Res. 863, 106-111.
58. + enhances potassium evoked striatal dopamine release through an Ω -conotoxin-insensitive, tetrodotoxin- and nimodipine-sensitive calcium dependent mechanism. Ann. N. Y. Acad. Sci. 635, 393-396.
59. Vaccari, A., and Saba, P. (1995) The tyramine-labeled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins. Eur. J. Pharmacol. 292, 309-314.
60. Lotharius, J., and O'Malley, K. L. (2000) The parkinsonian-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. J. Biol. Chem. 275, 38581-38588.
61. Cooper, J. M., and Schapira, A. H. V. (1997) Mitochondrial dysfunction in neurodegeneration. J. Bioenerg. Biomembr. 29, 175-183.
62. Cao, C. J., Eldefrawi, A. T., and Eldefrawi, M. E. (1990) ATP-regulated neuronal catecholamine uptake: a new mechanism. Life Sci. 47, 655-667.
63. Pérez-Otaño, I., Herrero, M. T., Oset, C., de Ceballos, M. L., Luquin, M. L., Obeso, J. A., and Del R'o, J. (1991) Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res. 567, 127-132.
64. +). Neurosci. Lett. 85, 228-232.
65. 2+ channel antagonists on striatal dopamine and DOPA release, studied by in vivo microdialysis. Br. J. Pharmacol. 123, 805-814.
66. Tanaka, T., Horio, Y., Taketoshi, M., Imamura, I., Ando-Yamamoto, M., Kangawa, K., Matsuo, H., Kurodo, M., and Wada, H. (1989) Molecular cloning and sequencing of a cDNA of rat dopa decarboxylase: partial amino acid homologies with other enzymes synthesizing catecholamines. Proc. Natl. Acad. Sci. U.S.A. 86, 8142-8146.
67. Ishii, S., Mizuguchi, H., Nishino, J., Hayashi, H., and Kagamiyama, H. (1996) Functionally important residues of aromatic L-amino acid decarboxylase probed by sequence alignment and site-directed mutagenesis. J. Biochem. (Tokyo) 120, 369-376.
68. Spencer, J. P. E., Jenner, P., Daniel, S. E., Lees, A. J., Marsden, D. C., and Halliwell, B. (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson's disease. Possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71, 2112-2122.
69. Kuhn, D. M., and Arthur, R. (1998) Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. J. Neurosci. 18, 7111-7117.
70. Kuhn, D. M., Arthur, R. E., Thomas, D. M., and Elferink, L. A. (1999) Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein. J. Neurochem. 73, 1309-1317.
71. Olney, J. W., Zorumski, C. F., Stewart, G. R., Price, M. T., Wang, G., and Labruyere, J. (1990) Excitotoxicity of L-DOPA and 6-OH-DOPA: implications for Parkinson's and Huntington's diseases. Exp. Neurol. 108, 269-272.
72. Blandini, F., Porter, R. H. P., and Greenamyre, J. T. (1996) Glutamate and Parkinson's disease. Mol. Neurobiol. 12, 73-94.
73. +. J. Neurochem. 73, 750-757.
74. 2+-dependent and tetrodotoxin-sensitive release of endogenous glutamate from rat striatal slices. Brain Res. 617, 167-170.
75. Furukawa, N., Arai, N., Goshima, Y., Miyamae, T., Ohshima, E., Suzuki, F., Fujita, K., and Misu, Y. (2001) Endogenously released DOPA is a causal factor for glutamate release and resultant delayed neuronal cell death by transient ischemia in rat striata. J. Neurochem. 76, 815-824.
76. Nash, J. F., and Yamamoto, B. K. (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581, 237-243.